Navigation Links
FDA Approves Soliris for Rare Pediatric Blood Disorder
Date:9/23/2011

SILVER SPRING, Md., Sept. 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Atypical HUS accounts for 5 to 10 percent of all cases of hemolytic uremic syndrome. The disease disproportionately affects children.

Soliris is a targeted therapy that works by inhibiting proteins that play a role in aHUS.  The FDA first approved Soliris in March 2007 to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death.  Soliris is classified as an orphan drug. Orphan drugs are those that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

There are no other FDA-approved treatments for aHUS, and the safety and effectiveness of current standard treatment, plasma therapy (plasma exchange or fresh frozen plasma infusion), have not been studied in well controlled trials.

"This is the first approval of a drug for treating this life-threatening disease, and the first approval for use of Soliris in children," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "This approval underscores how an increased understanding of the biology of a disease and of how a drug interacts with that process can expedite drug development."

Soliris' safety and effectiveness were established in two single-arm trials in 37 adults and adolescent patients with aHUS and one retrospective study in 19 pediatric patients and 11 adult patients with aHUS.  Patients treated with Soliri
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
2. FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
3. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
4. FDA Approves Adcetris to Treat Two Types of Lymphoma
5. FDA Approves the First Specific Treatment for Scorpion Stings
6. Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director
7. FDA Tentatively Approves Intellijects Lead Product, e-cue™
8. FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US
9. FDA Approves Vaccines for the 2011-2012 Influenza Season
10. FDA Approves Boostrix to Prevent Tetanus, Diphtheria, and Pertussis in Older People
11. FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015 Jintian Pharmaceutical Group Limited ("Jintian ... Mr. Jin Dongtao, chairman and executive director purchased 40,000,000 ... of the existing entire issued share capital of the ... with the total amount of approximately HK$113 million. Upon ... will increase from 45.17% to 47.17%. ...
(Date:4/1/2015)... 1, 2015  For many businesses and industries just ... the case, having the right management software can be ... better than software solutions company TraxStar Technologies , ... the company announced the release of the newest version ... "QATrax ...
(Date:4/1/2015)... WAYNE, Pa. , April 1, 2015 /PRNewswire/ ... fully integrated specialty pharmaceutical company focused on developing, ... the pricing of an offering of $60.0 million ... due 2020 (the "notes") in a private placement ... under the Securities Act of 1933, as amended ...
Breaking Medicine Technology:Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 2Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 4Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 5TraxStar Technologies Announces Latest QATrax Test Lab Management Software Now Available 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7
... , FRANKLIN LAKES, N.J., Dec. 29 ... matrix engineering, announced today that Dr. Shu-Tung Li, the ... as New Jersey,s 2009 Executive of the Year, an ... and Mattia, Certified Public Accountants and Consultants. In ...
... , , , , ... developer of medical device technology for the safe handling, ... Webinar program supporting its culture of safety initiative for ... Culture of Safety in Pharmacy: Lessons Learned," features an ...
Cached Medicine Technology:Shu-Tung Li, Founder and CEO of Collagen Matrix, Inc. Honored as 2009 New Jersey Executive of the Year and Company Named Sixteenth Fastest Growing Company 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 3
(Date:4/1/2015)... (PRWEB) April 01, 2015 NTOCC today ... transitions of care tools that seek to improve care ... this program, NTOCC hopes to bring light to tools ... transitions of care across the healthcare industry through the ... that advance collaborative patient-care. Following that vision, the Knowledge ...
(Date:4/1/2015)... IL (PRWEB) April 01, 2015 ... was joined by other First Spouses from across ... event on March 21, 2015, World Down Syndrome ... for, the rapidly advancing area of Down syndrome ... participating states included Alabama, Alaska, American Samoa, Arizona, ...
(Date:4/1/2015)... Springs, FL (PRWEB) April 01, 2015 ... nation’s leading innovative specialty pharmacies, has released a new ... latest treatment guidelines for treating chronic hepatitis C virus ... treatment guidelines based on information from the American Association ... credible, scientific sources. , Numerous new direct-acting oral medications ...
(Date:4/1/2015)... Dr Roz Kamani, a Vancouver medical aesthetic doctor, ... patients an opportunity to learn more about the latest ... which is an exclusive VIP event conducted three times ... Clinic. It is attended by Dr Roz Kamani’s suppliers ... and services that are on offer. , In ...
(Date:4/1/2015)... April 01, 2015 South Florida’s newest ... Certificate of Authority (PCOA) approval from the State of ... the ongoing development of a retirement community that will ... wellness and spiritual development. , America’s aging population is ... the housing needs of seniors, according to a recent ...
Breaking Medicine News(10 mins):Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 2Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 3Health News:Governor First Spouses Join with New Jersey First Lady Mary Pat Christie to Support Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment 2Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Casa Sant’Angelo Receives Approval for New Retirement Living 2
... ... supports on BetterBraces.com. , ... Diego, CA (PRWEB) January 22, 2010 -- DonJoy Velocity ankle braces were the ... total sales of Velocity ankle braces were double that of other ankle supports sold on ...
... factors from younger mice, researchers found , WEDNESDAY, Jan. 27 ... old stem cells in the blood act like young stem ... the aging process. , Taking certain factors from the blood ... old stem cells take on the characteristics of younger stem ...
... is among several that use a variation of MRI ... new imaging technology promises to achieve the long-sought goal ... require the most aggressive treatment, researchers report. , Magnetic ... of suspected cancerous tissue, gave good results in a ...
... ... Florida , ... 2010 -- USA Football, the sport’s national governing body on youth and amateur levels, announced ... list of partners for USA Football’s “Team USA vs. The World” game, presented ...
... CALIFANO CONTINUES AS CHAIRMAN , NEW YORK , ... (CASA) at Columbia University announced today that William H. ... School of Public Service, will become President and Chief Executive Officer ... Califano, Jr. , the former U.S. Secretary of Health, Education, and Welfare ...
... , , WASHINGTON , Jan. 27 ... Washington, D.C. , on Saturday, May 1, 2010 ... The focus of this year,s forum will be expansion and implementation ... the National Board of Certification for Medical Interpreters. , "While medical ...
Cached Medicine News:Health News:DonJoy Velocity Ankle Brace is the Best Selling Ankle Brace in 2009 2Health News:Aging of Blood Stem Cells May Be Reversible 2Health News:New Scan May Help Find Aggressive Prostate Tumors 2Health News:New Scan May Help Find Aggressive Prostate Tumors 3Health News:The Andrews Institute and Reebok Join Partner Roster for USA Football's “Team USA vs. The World” Game, Presented By Riddell 2Health News:The Andrews Institute and Reebok Join Partner Roster for USA Football's “Team USA vs. The World” Game, Presented By Riddell 3Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 3Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 4Health News:Leaders and Advocates Convene in Washington, D.C. for Fourth Annual National Medical Interpreter Certification - Open Forum 2Health News:Leaders and Advocates Convene in Washington, D.C. for Fourth Annual National Medical Interpreter Certification - Open Forum 3Health News:Leaders and Advocates Convene in Washington, D.C. for Fourth Annual National Medical Interpreter Certification - Open Forum 4
... Modes of Operation: , Standby: A standby switch ... , Double Burst : 2 60-ms bursts of 50 ... , Twitch: 1 s (1 pulse/s); 2 Hz (2 ... 100 Hz (100 pulses/s) , Train-Of-Four: 4 pulses/2 s; ...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
... Optilene Mesh LP is a super-light ... The foreign body reaction is reduced considerably. ... mesh for all open hernia repair procedures. ... its excellent flexibility Optilene Mesh LP adapts ...
Medicine Products: